{"id":9874,"date":"2015-04-24T07:28:27","date_gmt":"2015-04-24T05:28:27","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=9874"},"modified":"2015-04-24T12:30:31","modified_gmt":"2015-04-24T10:30:31","slug":"stati-uniti-glaxosmithkline-richiama-17-milioni-dosi-di-vaccino-influenzale","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/stati-uniti-glaxosmithkline-richiama-17-milioni-dosi-di-vaccino-influenzale\/","title":{"rendered":"United States: GlaxoSmithKline recalls 1.7 million doses of flu vaccine"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/www.informasalus.it\/data\/foto\/s\/stati-uniti-glaxosmithkline-richiama-1-7-milioni-dosi-di-vaccino-influenzale_4093.jpg\" alt=\"vaccini\" width=\"212\" height=\"150\" \/>There<strong> GlaxosmithKline<\/strong> is recalling remaining doses of a Flulaval quadrivalent flu vaccine due to efficacy issues. The letter was sent to approximately 1,000 customers across the United States, including wholesale distributors, pharmacies, government agencies and physicians. The recall affects about 1.7 million doses, of which more than the 99% of vaccines.<\/p>\n<p>According to reports from the pharmaceutical company, the measure would not be related to vaccine safety problems and was adopted for precautionary purposes since a variability in the production process was detected that could attenuate its ability to induce an antibody response in the long run term. THE <strong>recalled vaccines<\/strong> they represent approximately 7% of the total 24 million doses of GlaxoSmithKline flu vaccine distributed in the United States this season.<\/p>\n<p>Of <a href=\"http:\/\/www.informasalus.it\/it\/articoli\/glaxosmithkline-ritira-vaccino.php\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">InformaSalus.it editorial staff 04\/23\/2015<\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>La GlaxosmithKline sta richiamando le rimanenti dosi di un vaccino antinfluenzale quadrivalente Flulaval\u00a0 a causa di problemi di efficacia. La lettera \u00e8 stata inviata a circa mille clienti in tutto gli Stati Uniti, tra cui distributori all&#8217;ingrosso, farmacie, agenzie governative e medici. Il\u00a0richiamo riguarda\u00a0 circa 1,7 milioni di dosi, di cui pi\u00f9 del 99% dei &hellip;<\/p>","protected":false},"author":4,"featured_media":6050,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[34,39],"class_list":["post-9874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-gsk","tag-vaccini"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/9874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=9874"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/9874\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/6050"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=9874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=9874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=9874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}